Literature DB >> 36199899

Seven cancer patients receiving guselkumab for treatment of moderate-to-severe psoriasis.

Luca Mastorino1, Niccolò Siliquini1, Gianluca Avallone1, Michela Ortoncelli1, Pietro Quaglino1, Paolo Dapavo1, Simone Ribero1.   

Abstract

Entities:  

Keywords:  Biological therapy; Cancer; Guselkumab; IL-23; Neoplasia; Psoriasis

Year:  2022        PMID： 36199899      PMCID： PMC9527684          DOI： 10.4081/dr.2022.9282

Source DB:  PubMed          Journal:  Dermatol Reports        ISSN： 2036-7392


× No keyword cloud information.
  7 in total

1.  EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 2: specific clinical and comorbid situations.

Authors:  A Nast; C Smith; P I Spuls; G Avila Valle; Z Bata-Csörgö; H Boonen; E De Jong; I Garcia-Doval; P Gisondi; D Kaur-Knudsen; S Mahil; T Mälkönen; J T Maul; S Mburu; U Mrowietz; K Reich; E Remenyik; K M Rønholt; P G Sator; M Schmitt-Egenolf; M Sikora; K Strömer; O Sundnes; D Trigos; G Van Der Kraaij; N Yawalkar; C Dressler
Journal:  J Eur Acad Dermatol Venereol       Date:  2021-02       Impact factor: 6.166

Review 2.  A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis.

Authors:  Jawad Bilal; Adam Berlinberg; Sandipan Bhattacharjee; Jaren Trost; Irbaz Bin Riaz; Drew J B Kurtzman
Journal:  J Dermatolog Treat       Date:  2018-03-28       Impact factor: 3.359

3.  Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.

Authors:  Kristian Reich; April W Armstrong; Peter Foley; Michael Song; Yasmine Wasfi; Bruce Randazzo; Shu Li; Y-K Shen; Kenneth B Gordon
Journal:  J Am Acad Dermatol       Date:  2017-01-02       Impact factor: 11.527

4.  Treatment of Psoriasis With Biologics and Apremilast in Patients With a History of Malignancy: A Retrospective Chart Review

Authors:  Jared S. Kahn; Rachel G. Casseres; Min J. Her; Nicole Dumont; Alice B. Gottlieb; David Rosmarin
Journal:  J Drugs Dermatol       Date:  2019-04-01       Impact factor: 2.114

5.  IL-17A inhibitors in patients with chronic plaque psoriasis and history of malignancy: A case series with systematic literature review.

Authors:  Francesco Bellinato; Paolo Gisondi; Martina Maurelli; Giampiero Girolomoni
Journal:  Dermatol Ther       Date:  2021-02-25       Impact factor: 2.851

Review 6.  New insights into the IL-12 and IL-23: From a molecular basis to clinical application in immune-mediated inflammation and cancers.

Authors:  I-Tsu Chyuan; Jenn-Haung Lai
Journal:  Biochem Pharmacol       Date:  2020-03-23       Impact factor: 5.858
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.